Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17594581 | 1.00 | AURKA (0.32) | AURKATTKAURKBINCENPPIK3CA | |
| SCHEMBL25293011 | 0.81 | OPRK1 (0.32) | HTTSMN1; SMN2DYRK1A | |
| SCHEMBL25242198 | 0.81 | OPRK1 (0.32) | HTTSMN1; SMN2DYRK1A | |
| SCHEMBL1465179 | 0.80 | ERN1 (0.35) | AURKATTKAURKBINCENPPIK3CA | |
| SCHEMBL1465182 | 0.80 | ERN1 (0.35) | AURKATTKAURKBINCENPPIK3CA | |
| SCHEMBL1431924 | 0.79 | MAPT (0.33) | POLBRAB9AERN1 | |
| SCHEMBL1465992 | 0.79 | MAPT (0.33) | POLBRAB9AERN1 | |
| SCHEMBL671095 | 0.79 | ERN1 (0.46) | PIK3CAMTORSMN1; SMN2ERN1 | |
| SCHEMBL2258552 | 0.78 | KDM4E (0.42) | SMN1; SMN2 | |
| SCHEMBL1078728 | 0.78 | CNR2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191478-B1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | NOVARTIS AG (CH) | 2019-01-01 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| EP-3191478-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | Novartis AG (CH) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016038582-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | AURKA 509/4885TTK 344/4885AURKB 445/4885 |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | BRAF, RAF1, ARAF | AURKA 509/4885TTK 344/4885AURKB 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.